-
Product Name
DXd Monoclonal Antibody
- Documents
-
Description
Product has been tested in direct ELISA.
-
Tested applications
ELISA
-
Species reactivity
Chemical
-
Isotype
Mouse IgG1, κ
-
Preparation
DXd conjugated with BSA. Protein G affinity purified
-
Clonality
Monoclonal
-
Formulation
PBS(pH7.4), lyophilized. Reconstitution: Adding sterile water, prepare a stock solution of 2.0 mg/ml.
-
Storage instructions
Store at -20℃. Avoid freeze / thaw cycles.
-
Applications
ELISA: 1:5,000-1:20,000
-
Validations
ELISA Binding Assay of Anti-Dxd Antibody to different proteins.
ELISA analysis of Anti-Dxd Monoclonal Antibody with Dxd-BSA, BSA and Dxd ADC. Anti-Dxd Monoclonal Antibody can bind to Dxd-BSA or Dxd ADC but not carrier protein.
ELISA Binding Assay of Anti-Dxd Antibody
Immobilized Dxd ADC at 2μg/mL (100μL/well) can bind anti-Dxd mouse monoclonal antibody.
-
Background
DXd is a derivative of Exatecan (DX-8951). Dxd (Deruxtecan) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 µM, of 10-fold potency compared to the active metabolite of irinotecan (SN-38) in vitro. Dxd has been used as the conjugated payload of the HER2-targeting ADC (DS-8201a) and some other ADCs.
-
References
- Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Preclinical Efficacy of DS-8201a, a Novel HER2-Targeting ADC[J]. Clinical Cancer Research, 2016, 22(20): 5097-5108.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"